Bain Capital

Bain Capital

About Bain Capital

Simplify's Rating
Why Bain Capital is rated
C
Rated C on Competitive Edge
Rated B on Growth Potential
Rated D+ on Rating Differentiation

Industries

Venture Capital

Social Impact

Financial Services

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

$11.5B

Headquarters

Boston, Massachusetts

Founded

1984

Overview

Simplify Jobs

Simplify's Take

What believers are saying

  • Italmatch acquisition taps into growing demand for specialty chemical additives.
  • Mitsubishi Tanabe deal offers growth in Japan's life sciences industry.
  • Milacron investment benefits from rising demand for sustainable materials in automotive.

What critics are saying

  • Increased competition in Japanese IT sector limits expansion opportunities.
  • Regulatory hurdles may delay Italmatch Chemicals acquisition.
  • Integration challenges may arise from Apleona's significant size and complexity.

What makes Bain Capital unique

  • Bain Capital's acquisition of Italmatch Chemicals enhances its specialty chemical sector expertise.
  • The Mitsubishi Tanabe acquisition aligns with Japan's relaxed drug approval regulations.
  • Bain Capital's investment in Milacron supports the shift to sustainable plastic solutions.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$11488.9M

Above

Industry Average

Funded Over

0 Rounds

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Latest Nigerian News
Feb 18th, 2025
Bain Capital says it will not launch a tender offer for Fuji Soft, after KKR raised its offer earlier in February for the Japanese IT company, valued at $4B+ (Reuters)

Bain Capital says it will not launch a tender offer for Fuji Soft, after KKR raised its offer earlier in February for the Japanese IT company, valued at $4B+ (Reuters).

SafeBond Medical
Feb 16th, 2025
Bain Capital Acquires Mitsubishi Tanabe for $3.3B

Bain Capital has acquired Tanabe Mitsubishi Pharmaceutical from Mitsubishi Chemical Group for $3.3 billion. The deal, expected to close in Q3 2025, will make Tanabe an independent company. Bain Capital aims to introduce innovative drugs to Japan and leverage Tanabe's platform for commercial collaborations. This acquisition aligns with Japan's relaxed drug approval regulations, offering growth opportunities in the Japanese life sciences industry.

Bain Capital
Feb 14th, 2025
Bain Capital Acquires Italmatch Chemicals

Bain Capital Private Equity has signed a definitive agreement to acquire Italmatch Chemicals from Ardian. Italmatch, founded in 1997, is a global specialty chemical additive manufacturer with 2017 sales of approximately €400 million. The company operates 17 manufacturing sites globally. The transaction, subject to regulatory approval, marks a new growth phase for Italmatch, leveraging Bain Capital's expertise in the chemical sector.

PE Insights
Feb 14th, 2025
Bain Capital finalises €4bn acquisition of Apleona from PAI Partners | Private Equity Insights

Bain Capital finalises €4bn acquisition of Apleona from PAI Partners Bain Capital completed the acquisition of German facility management company Apleona from PAI Partners in a deal valued at approximately €4bn ($4.2bn). The transaction marks one of the most significant private equity deals in the European facility management sector in recent years. Apleona, formerly part […]

Business Wire
Feb 11th, 2025
SelectQuote Announces $350 Million Strategic Investment from Bain Capital, Morgan Stanley Private Credit and Newlight Partners

SelectQuote, Inc. (NYSE: SLQT) (the “Company”), a leading distributor of Medicare insurance policies and owner of a rapidly-growing healthcare service

Recently Posted Jobs

Sign up to get curated job recommendations

Bain Capital is Hiring for 0 Jobs on Simplify!

Find jobs on Simplify and start your career today

💡
We update Bain Capital's jobs every 8 hours, so check again soon! Browse all jobs →